NUNalân Utku

Nalân Utku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nalân Utku has a total of 130 co-authors. Here are the top co-authors by number of shared publications:

  • Hans-Dieter Volk

    Institute of Medical Immunology, Campus Mitte, Charite, Humboldt-University of Berlin, Schumannstr. 20/21, D-10117 Berlin, Germany

    6 shared publications
  • Grit-Carsta Bulwin

    CellAct Pharma GmbH, Berlin, Germany

    5 shared publications
  • Thomas Heinemann

    Kekulé-Institut für Organische Chemie und Biochemie der Universität Bonn , Bonn

    5 shared publications
  • Francisca Beato

    Institute for Medical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany

    3 shared publications
  • Mirko Schlawinsky

    CellAct Pharma GmbH, Berlin, Germany

    3 shared publications
  • Richard S. Blumberg

    Division of Gastroenterology, Brigham and Women’s Hospital , Boston, MA 02115

    3 shared publications

Latest Publications

  • Open Access

    Immune Regulatory 1 Cells: A Novel and Potent Subset of Human T Regulatory Cells

    by Nicolas Krause, Jörg Mengwasser, Elpida Phithak, Francisca Beato, Marc Appis, Edgar Louis Milford, Johan Pratschke, Igor Sauer, Anja Kuehl, Arndt Vogel, et al.

    A subset of T regulatory cells (Tregs), identified by TIRC7 (T cell immune response cDNA 7) expression is designated as Immune Regulatory 1 Cells (IR1 cells). TIRC7 is an immune checkpoint inhibitor, co-localized with the T- cell receptor, HLA-DR and CTLA-4 during T-cell activation, which delivers regulatory signals via binding to its ligand, HLA-DR α2 domain. IR1 cells express FOXP3, and multiple other markers associated with immune suppression. They constitute as much as 10% of Tregs. IR1 cells strongly inhibit proliferation in mixed lymphocyte reactions, where they express high levels of IL-10. Ex vivo expansion of Tregs over 2 weeks in the presence of an agonist TIRC7 antibody disproportionately expands the IR1 Treg subset, while maintaining high expression of suppressive markers including CD39, IL-10, LAP and GARP. Ex vivo expanded IR1 cells are a potent, homogeneous, stable set of suppressor Tregs with the potential to modulate immune dysregulation. The characteristics of IR1 cells suggest a therapeutic advantage over polyclonal Tregs for therapeutic interventions. Early restoration of immune homeostasis using IR1 cells has the potential to fundamentally alter the natural history of conditions characterized by abnormalities in the T regulatory cell compartment.


  • Open Access

    Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study

    by Ulrich-Frank Pape, Stefan Kasper, Johannes Meiler, Marianne Sinn, Arndt Vogel, Lothar Müller, Oswald Burkhard, Karel Caca, Steffen Heeg, Petra Büchner-Steudel, et al.

    CAP7.1 is a novel topoisomerase II inhibitor, converted to active etoposide via carboxylesterase 2 (CES2), with signals of efficacy in treatment-refractory solid tumours. In a Phase II trial, 27 patients with advanced biliary tract cancers (BTC) were randomised 1:1 to CAP7.1 plus best supportive care (BSC), or BSC alone, with crossover to CAP7.1 upon disease progression. The primary objective was disease control rate (DCR) following 28-day cycles of CAP7.1 (200/150 mg/m2; iv), or BSC until progression. Secondary objectives included progression-free survival (PFS), time-to-treatment failure (TTF), overall survival (OS) and safety. Fourteen patients received CAP7.1 and 13 BSC. DCR favoured CAP7.1 vs. BSC (50% vs. 20%; treatment difference: 30%, 95%CI −18.44, 69.22, full analysis set [FAS]), with disease progression in 40% vs. 70%, respectively. Significantly longer median PFS was achieved for CAP7.1 vs. BSC: 66 vs. 39 days, respectively (hazard ratio [HR] 0.31; 95%CI 0.11, 0.86; p = 0.009; FAS). Similar trends were observed for TTF and OS. CES2-positive patients had longer median PFS (158 vs. 56 days) and OS (228 vs. 82 days) vs. CES2-negative patients. Adverse events were predictable, dose-dependent and consistent with those previously observed with etoposide. These efficacy and safety findings in second-line BTC warrant further clinical investigation of CAP7.1.


  • Open Access

    A review of systemic therapy in biliary tract carcinoma

    by Holger Jansen, Ulrich-Frank Pape, Nalân Utku

    Biliary tract carcinoma (BTC) has a poor prognosis and is increasing in incidence. Although surgery, chemotherapy and other treatment modalities have improved, surgery remains the only potential curative treatment and is appropriate for only those few patients who present with localized, resectable disease. However, for the majority of patients, unresectable disease is evident at diagnosis and about 95% of patients die within 10 years, despite the majority receiving chemotherapy. Long-term survival is significantly greater for patients with resected BTC compared to those with unresectable disease. In unresected disease, life expectancy is limited, with first-line gemcitabine/cisplatin (GEM/CIS) accepted as standard of care. Currently no standard second-line regimen which provides significant improvement of clinical outcomes exists for those who present with refractory disease or who relapse after first-line treatment. Of particular importance is establishing the impact of best supportive care (BSC) as a benchmark for survival outcomes to which the impact of treatment modalities can be compared. Survival outcome often differs significantly for patients with different prognostic factor profiles even when receiving the same therapy so that it can be difficult to predict which patient subgroup might benefit most from which therapy. Therefore, the influence of prognostic factors on survival under different therapies as well as under BSC needs to be further assessed in order to arrive at truly evidence-based, best therapeutic decisions for individual patients. Encouraging new research into the genomic landscape of BTC may help to further subdivide the BTC population into molecular-genetic clusters likely to be sensitive to different targeted therapy approaches leading to further improvements in survival. Consequently, an unmet need exists not only to develop new and more effective therapies for this devastating disease, but also to integrate original research findings into a more complex, dynamic, individualized therapeutic decision model to aid clinicians in making evidence-based, best therapeutic decisions for individual patients.


  • Open Access

    Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma

    by Benjamin Goeppert, Marcus Renner, Stephan Singer, Thomas Albrecht, Qiangnu Zhang, Arianeb Mehrabi, Anita Pathil, Christoph Springfeld, Bruno Köhler, Christian Rupp, et al.

    Carboxylesterase 2 (CES2) is instrumental for conversion of ester-containing prodrugs in cancer treatment. Novel treatment strategies are exceedingly needed for cholangiocarcinoma (CCA) patients. Here, we assessed CES2 expression by immunohistochemistry in a CCA cohort comprising 171 non-liver fluke associated, intrahepatic (n = 72) and extrahepatic (perihilar: n = 56; distal: n = 43) CCAs. Additionally, 80 samples of high-grade biliary intraepithelial neoplastic tissues and 158 corresponding samples of histological normal, non-neoplastic biliary tract tissues were included. CES2 expression was highest in non-neoplastic biliary tissue and significantly decreased in CCA. Patients showing any CES2 expression in tumor cells had a significantly better overall survival compared to negative cases (p = 0.008). This survival benefit was also maintained after stratification of CES2-positive cases, by comparing low, medium and high CES2 expression levels (p-trend = 0.0006). Evaluation of CCA subtypes showed the survival difference to be restricted to extrahepatic tumors. Correlation of CES2 expression with data of tumor-infiltrating immune cells showed that particularly CD8+ T cells were more frequently detected in CES2-positive CCAs. Furthermore, treatment of CCA cell lines with the prodrug Irinotecan reduced cell viability, increased cytotoxicity and modulated inflammatory gene expression. In conclusion, reduced CES2 expression is associated with poor outcome and low CD8+ T cell infiltration in CCA patients. Further clinical studies could show, whether CES2 expression may serve as a predictive marker in patients treated with prodrugs converted by CES2.


  • First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours

    by U. Keilholz, L. Rohde, P. Mehlitz, M. Knoedler, A. Schmittel, V. Kümmerlen, K. Klinghammer, P. Treasure, M. Lassus, G. Steventon, et al.


  • Tissue-infiltrating plasma cells are an important source of carboxylesterase 2 contributing to the therapeutic efficacy of prodrugs

    by Anja A. Kühl, Ulrike Erben, Constanze Cieluch, Simone Spieckermann, Jörn Gröne, Philipp Lohneis, Ulrich Frank Pape, Ruza Arsenic, Nalân Utku


  • Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer.

    by Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, et al.

    E15602 Background: The aim of this study was to describe the population pharmacokinietics (PK) of CAP7.1, the prodrug of etoposide, and to describe how changes in total target lesion (TTL) size in biliary tract cancer (BTC) patients depend on treatment with CAP7.1. Methods: Non linear mixed effects modeling with Monolix was used to develop a population PK model. Data for the population PK model was from an open label, dose escalation phase I study and the ongoing randomized, multicenter phase II trial in BTC patients. Data from a total of 39 patients with 434 observations was available for PK modeling. Variability in CAP7.1 plasma concentrations exeeded those of etoposide; for this reason a dose-etoposide PK model was developed without taking into account CAP7.1 concentrations. The individual a posteriori PK model parameter estimates were then used with Simulx to simulate etoposide AUC0-24h , cmax and cmin for each BTC patient and compared with the individual changes in TTL size. Results: Etoposide PK was best described with a two compartmental model with a first order metabolic conversion rate and with linear clearance from the central compartment. The metabolic rate was 0.39 1/h (CV 44%), the clearance 3.2 L/h (CV 56%), the first volume 6.2 L (CV 37%), and the two exchange rates between the two compartments were k12 = 0.53 and k21 = 0.2 1/h. The calculated terminal half life of etoposide was 7.9 h. Linear regression analysis between the simulated AUC0-24h and change in TTL size showed that a higher AUC0-24h was associated with a lower increase in TTL size (R2= 0.172). For an AUC0-24h larger than 100 h ug/mL six out of eight BTC patients had an increase in TTL size of less than 20%. Similarly, a higher cmax (R2= 0.177) or cmin (R2= 0.11) were associated with a larger effect on TTL size although less pronounced for cmin . Conclusions: While the PK of CAP7.1 was variable the dose-etoposide population PK could be well described. The emerging pattern from the data analysis showed that for a higher etoposide AUC0-24h a larger fraction of patients could maintain the increase in TTL size below 20% for the observational period in the phase II study in BTC Clinical trial information: NCT02094560.

  • Improving the Outcomes: Developing Cancer Therapeutics

    by Nalân Utku

    Oncology therapeutics are less likely to reach the market than other therapeutics, at a higher cost, and only approximately one in ten cancer drugs in clinical development actually reach the market. To improve, there need to be new approaches to oncology research and development, based on understanding cancer biology and improving preclinical models and clinical trials, such as more use of biomarkers and evaluation of other targets including cancer stem cells and use of combination therapies. Biomarkers can be used to make early go/no-go decisions in drug development and can speed up drug development by selecting patients who will benefit and excluding patients likely to experience severe side effects, but they need validation before use. New approaches to preclinical and clinical trials can also speed up and improve the development of cancer therapeutics.


  • The End of Cytotoxics?

    by Nalân Utku

    Cytotoxic drugs were the first form of cancer chemotherapy to be established, but they can have quite severe side effects. Cytotoxics attack all rapidly dividing cells, including healthy cells and cancer cells. They can therefore cause side effects such as loss of hair, damage to the skin and mucosa, and damage to bone marrow, affecting the immune system. For this reason, the focus of some cancer research has moved from cytotoxics to targeted therapeutics, including monoclonal antibodies. Monoclonal antibodies can be very effective in patients who express the appropriate target; however, not all patients do, and some develop resistance. Monoclonal antibodies, like other biologicals, are also very costly. All is not lost for cytotoxics. Because they have been around for so long, there is an abundance of data on their modes of action. Based on these data, researchers have developed newer cytotoxics that are more effective and have fewer side effects, and approaches that deliver cytotoxics more safely or target them to tumours.

  • Open Access

    HLA-DR Alpha 2 Mediates Negative Signalling via Binding to Tirc7 Leading to Anti-Inflammatory and Apoptotic Effects in Lymphocytes In Vitro and In Vivo

    by Grit-Carsta Bulwin, Stephanie Wälter, Mirko Schlawinsky, Thomas Heinemann, Anke Schulze, Wolfgang Höhne, Gerd Krause, Wiltrud Kalka-Moll, Patricia Fraser, Hans-Dieter Volk, et al.

    Classically, HLA-DR expressed on antigen presenting cells (APC) initiates lymphocyte activation via presentation of peptides to TCR bearing CD4+ T-Cells. Here we demonstrate that HLA-DR alpha 2 domain (sHLA-DRα2) also induces negative signals by engaging TIRC7 on lymphocytes. This interaction inhibits proliferation and induces apoptosis in CD4+ and CD8+ T-cells via activation of the intrinsic pathway. Proliferation inhibition is associated with SHP-1 recruitment by TIRC7, decreased phosphorylation of STAT4, TCR-ζ chain & ZAP70, and inhibition of IFN-γ and FasL expression. HLA-DRα2 and TIRC7 co-localize at the APC-T cell interaction site. Triggering HLA-DR - TIRC7 pathway demonstrates that sHLA-DRα2 treatment inhibits proinflammatory-inflammatory cytokine expression in APC & T cells after lipopolysaccaride (LPS) stimulation in vitro and induces apoptosis in vivo. These results suggest a novel antiproliferative role for HLA-DR mediated via TIRC7, revise the notion of an exclusive stimulatory interaction of HLA-DR with CD4+ T cells and highlights a novel physiologically relevant regulatory pathway.